Efficacy of the combined therapy of sitagliptin and insulin in japanese type 2 diabetic patients
Not Applicable
- Conditions
- type 2 diabetes
- Registration Number
- JPRN-UMIN000007075
- Lead Sponsor
- Fukuoka university, school of medicine, department of endocrinology and diabetes mellitus
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 50
Inclusion Criteria
Not provided
Exclusion Criteria
type 1 diabetic patients insulin dependent diabetes mellitus renal failure history of ketosis
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method blood glucose HbA1c Continuous Glucose Monitering
- Secondary Outcome Measures
Name Time Method hypoglycemic attack
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie sitagliptin's synergistic effects with insulin in Japanese type 2 diabetes patients?
How does sitagliptin-insulin combination therapy compare to standard-of-care DPP-4 inhibitors in glycemic control for T2DM?
Which biomarkers correlate with improved beta-cell function in JPRN-UMIN000007075 sitagliptin-insulin trials?
What adverse event profiles are reported for DPP-4 inhibitor and insulin combination therapies in T2DM populations?
How do sitagliptin-insulin combinations compare to SGLT2 inhibitor-based regimens in Japanese type 2 diabetes management?